Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2014.
Targacept reported a net loss of $4.9 million for the third quarter of 2014, compared to $12.9 million for the third quarter of 2013.
Help employers find you! Check out all the jobs and post your resume.
